Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Peptron, Inc. specializes in the creation of peptide-based pharmaceuticals designed to manage chronic health conditions. The company's technological expertise encompasses advanced long-acting drug delivery systems and SmartDepot, an ultrasonic spray-drying technique utilized for developing sustained-release injectable microsphere drug formulations. Their research and development pipeline features several key products: Luphere Depot, which addresses prostate cancer, endometriosis, uterine fibroids, and puberty-related issues; SR-Octreotide (PT201) for treating acromegaly; SR-Exenatide (PT302) for type 2 diabetes; and SR-Exenatide (PT320), which is aimed at Parkinson's and Alzheimer's diseases. Founded in 1997, Peptron, Inc. is headquartered in Daejeon, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.